Compounded Semaglutide Cost: What Rows Really Say

Compounded semaglutide is sold on a monthly number, and the monthly number is the least reliable part of the offer. Two clinics can advertise figures forty dollars apart and be selling completely different things: one at a starting dose, one at every dose; one month to month, one only if you pay a year up front. This page takes the prices as they are actually filed and reports the distribution rather than a headline. Prices checked 2026-08-29.

What a month costs across the field

Of the 508 providers tracked here, 158 file a semaglutide price that is dated, unconditional and genuinely monthly. Those 158 run from $89 to $449. The median is $198. A quarter of them sit at or below $155 and a quarter at or above $249, which is the honest way to say that most of this market clusters between roughly $150 and $250 and the tails are long in both directions.

Broken into bands, 8 of the 158 come in under $100, 95 fall between $100 and $199, 45 between $200 and $299, and 10 sit at $300 or more. The verification dates on those rows run from 2026-06-06 to 2026-08-29, so the distribution is a summer-2026 snapshot, not a historical average.

The rows that did not qualify are as informative as the ones that did, and none of them were quietly averaged in. 172 semaglutide cells carry a condition that makes the figure something other than a standing monthly rate. 18 are brand-name prices, which belong on a different ladder. 14 carry no verification date, and an unverified price is the single best predictor of a wrong one. 146 publish no price at all. The sorted version of the qualifying rows is at cheapest semaglutide, and the compounded-only field is at best compounded semaglutide.

Why the spread is this wide

Four things move a compounded semaglutide price, and only one of them is the drug.

Dose is the first. 113 of the 362 semaglutide cells that carry a dollar figure are dose floors quoted at the starting strength, so the advertised number describes month one and not month six. Billing term is the second: 25 cells price a prepay plan, where a monthly figure exists only because a quarterly or annual charge was divided by three or twelve. What is bundled is the third. 8 cells are membership-gated, meaning a separate recurring fee sits beside the medication charge rather than inside it, and the Sesame Care review is an example of a listing whose lowest published figure is a care fee, not a drug price. Duration of the offer is the fourth: 14 cells are promotional rates and 6 are first-month rates that step up on the second bill.

There is a fifth variable that is not a discount at all. A combination product is a different product. The FDA has said it may consider a compounded drug that combines semaglutide with another ingredient, such as vitamin B12, to be essentially a copy of a commercially available drug product when the two are given by the same route for the same population². Where a listing prices a combination rather than plain semaglutide, as the Peter MD review records, the number beside it is not measuring the same thing as its neighbors.

Where the law stands, as of August 2026

Compounding is legal. Compounded drugs are not FDA-approved, and the agency states plainly that it "does not verify the safety, effectiveness or quality of compounded drugs before they are marketed"¹.

The lane matters more than it used to. Semaglutide could be compounded freely by both 503A pharmacies and 503B outsourcing facilities only while it sat on the FDA shortage list. The FDA declared that shortage resolved on February 21, 2025, the grace periods that followed have all expired, and the agency's own page now states that "Tirzepatide and semaglutide do not currently appear on the 503B bulks list or on FDA's drug shortage list"². On April 30, 2026 the FDA went further, announcing it was "proposing to exclude semaglutide, tirzepatide, and liraglutide on the 503B bulks list, finding no clinical need for outsourcing facilities to compound these drugs from bulk substances"³. The comment period on that notice closed on July 30, 2026⁴. Checking the Federal Register on 2026-08-29 turned up no final determination, so the proposal remains a proposal.

What that leaves is the 503A lane, compounding against an individual prescription, and it is why the market's supply picture and its price floor both look the way they do. The full timeline, with the court dates and what a provider's pharmacy line should say, is in is compounded GLP-1 legit and safe.

What a low number should make you ask

A price under $100 is not automatically a warning sign; 8 rows here file one and disclose the terms. What matters is whether the seller answers four questions in writing. Which pharmacy dispenses it, named. What dose the price covers. What billing term buys that price. And what is charged separately.

A number with no named pharmacy behind it is the pattern to walk away from, because the pharmacy is the only party that can be licensed, inspected or found. The step-by-step version of that check is in how to tell if a GLP-1 provider is legitimate.

What you are trading for the saving

The comparison that makes the price meaningful is the brand one. Novo Nordisk's own pharmacy publishes oral semaglutide at "$149 for each month of 1.5 mg, $199 per month for 4 mg and $299 per month for 9 mg and 25 mg," and the injection at $199 for the first two fills of the lowest doses, "then $349 per month for Wegovy 0.25 mg, 0.5 mg, 1 mg, 1.7 mg or 2.4 mg"⁵. The $198 median above therefore undercuts the brand maintenance figure and buys a product that has not been through FDA review — which is the whole trade, stated once.

It is worth remembering what the approved product was measured doing. In STEP 1, once-weekly semaglutide produced a mean weight reduction of roughly 15% of body weight over 68 weeks against about 2.4% on placebo⁶. No compounded preparation has its own trial behind it.

For the other molecule, the same breakdown is at compounded tirzepatide cost; for the brand and Medicare routes, see GLP-1 cost without insurance. Everything cited here is indexed in our research library.